Soluble CR1 derivatives
AssigneeAdProTech Limited
InventorsDanuta Ewa Irena Mossakowska, Ian Dodd, Anne Mary Freeman, Richard Anthony Godwin Smith
Life of this patent
Estimating the term…
Abstract
A soluble polypeptide comprising, in sequence, one to four short consensus repeats (SCR) selected from SCR 1, 2, 3 and 4 of long homologous repeat A (LHR-A) as the only structurally and functionally intact SCR domains of CR1 and including at least SCR3.
Claims16
A soluble polypeptide comprising no more than three short consensus repeats (SCR) of long homologous repeat A of Complement Receptor 1, wherein the polypeptide comprises SCR3 and at least one repeat selected from the group consisting of SCR1, SCR2, and SCR4.
A soluble polypeptide comprising no more than one short consensus repeat (SCR) of long homologous repeat A of Complement Receptor 1, wherein the polypeptide comprises SCR3.
A soluble polypeptide that can inhibit complement activation and that comprises no more than three short consensus repeats (SCR) of long homologous repeat A of Complement Receptor 1, wherein the soluble peptide is obtainable by
- expressing in a host cell a DNA molecule encoding the soluble polypeptide to produce the soluble polypeptide, wherein the DNA molecule encodes SCR3 and at least one repeat selected from the group consisting of SCR1, SCR2, and SCR4;
- and
- harvesting the soluble polypeptide.
A soluble polypeptide that can inhibit complement activation and that comprises no more than one short consensus repeat (SCR) of long homologous repeat A of Complement Receptor 1, wherein the soluble peptide is obtainable by
- expressing in a host cell a DNA molecule encoding SCR3 to produce the soluble polypeptide;
- and
- harvesting the soluble polypeptide.
A pharmaceutical composition for inhibiting complement activation, comprising a soluble polypeptide comprising no more than three short consensus repeats (SCR) of long homologous repeat A of Complement Receptor 1, wherein the polypeptide comprises SCR3 and at least one repeat selected from the group consisting of SCR1, SCR2, and SCR4.
A pharmaceutical composition for inhibiting complement activation, comprising a soluble polypeptide comprising no more than one short consensus repeat (SCR) of long homologous repeat A of Complement Receptor 1, wherein the polypeptide comprises SCR3.
A pharmaceutical composition for inhibiting complement activation, comprising a soluble polypeptide comprising no more than three short consensus repeats (SCR) of long homologous repeat A of Complement Receptor 1, wherein the soluble polypeptide is obtainable by
- expressing in a host cell a DNA molecule encoding SCR3 and at least one repeat selected from the group consisting of SCR1, SCR2, and SCR4 in order to produce the soluble protein;
- and
- harvesting the soluble polypeptide.
A pharmaceutical composition for inhibiting complement activation comprising a soluble polypeptide comprising no more than one short consensus repeat (SCR) of long homologous repeat A of Complement Receptor 1, wherein the soluble polypeptide is obtainable by
- expressing in a host cell a DNA molecule encoding SCR3 in order to produce the soluble polypeptide;
- and
- harvesting the soluble polypeptide.
A method of treating a patient in need of inhibition of complement activation, comprising
- administering to the patient a soluble polypeptide comprising no more than three short consensus repeats (SCR) of long homologous repeat A of Complement Receptor 1, wherein the polypeptide comprises SCR3 and at least one repeat selected from the group consisting of SCR1, SCR2, and SCR4.
A method of treating a patient in need of inhibition of complement activation, comprising
- administering to the patient a soluble polypeptide comprising no more than one short consensus repeat (SCR) of long homologous repeat A of Complement Receptor 1, wherein the polypeptide comprises SCR3.
Dependencies are inferred from the claim text.